U.S. Markets closed

AstraZeneca’s Lynparza Continues to Dominate

Margaret Patrick
AstraZeneca’s Lynparza Continues to Dominate

In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.